U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy

Ariceum Therapeutics United Kingdom United States of America Germany

225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows outstanding preclinical data and FDA IND clearancePhase I/II human trials set to commence in Q1 2025 as a 'theranostic' targeted radionuclide treatment View original content:https://www.prnewswire.co.uk/news-releases/us-fda-grants-orphan-drug-designation-to-ariceum-therapeutics-proprietary-radiopharmaceutical-cancer-therapy-302369403.html